OncoMatch/Clinical Trials/NCT06462365
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Is NCT06462365 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies TRX103 for hematologic malignancy.
Treatment: TRX103 — The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell transplantation (HSCT). It is anticipated that up to 36 Subjects will be enrolled during a 18-24 month enrollment period. TRX-103 will be infused one time post HSCT.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Chronic Lymphocytic Leukemia
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplant
Lab requirements
Kidney function
No significant renal dysfunction
Liver function
No significant hepatic dysfunction
Cardiac function
No significant cardiac dysfunction or on treatment to support cardiac dysfunction
history of significant renal, hepatic, pulmonary, or cardiac dysfunction, or on treatment to support cardiac dysfunction [excluded]. Have adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- Dana-Farber Cancer Institute · Boston, Massachusetts
- University of Minnesota · Minneapolis, Minnesota
- Memorial Sloan Kettering Cancer Center · New York, New York
- Fred Hutchinson Cancer Center · Seattle, Washington
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify